体重指数对分化型甲状腺癌侵袭性表现及临床结局的潜在影响
研究纳入1058例连续接受全甲状腺切除术并在首次放射性碘(131I)治疗时入组的分化型甲状腺癌(DTC)患者,按体重指数(BMI)分为体重不足、正常体重、超重和肥胖4组,评估诊断时组织学侵袭性及按2015年美国甲状腺协会(ATA)指南的临床结局。结果各组间组织学特征、ATA复发风险、131I给药活度、首次131I治疗后131I亲和转移性疾病患病率、随访中进一步治疗次数及临床反应均无差异。作者结论:在高加索人群中未发现BMI与DTC侵袭性或随访结局相关。
要点
- 1058例DTC患者按BMI分为4组,各组诊断时组织学特征无差异。
- 各组ATA复发风险、131I给药活度及131I亲和转移性疾病患病率无差异。
- 中位随访5.7年,各组进一步治疗次数及临床反应无差异。
核心结论
- 在高加索受试者研究组中,未发现BMI与DTC诊断时或随访期间的侵袭性相关。
- 作者认为DTC术后评估及治疗和随访策略应基于一般人群适用的风险分层,无需考虑BMI。
研究设计与样本
- 研究纳入1058例连续接受全甲状腺切除术并在首次放射性碘(131I)治疗时入组的分化型甲状腺癌(DTC)患者。
- 按BMI分为4组:体重不足(<18.5 kg/m2)、正常体重(18.5-24.9 kg/m2)、超重(25-29.9 kg/m2)、肥胖(≥30 kg/m2)。
- 评估诊断时DTC组织学侵袭性及按2015年美国甲状腺协会(ATA)指南的临床结局。
主要发现
- 各组间组织学特征无差异。
- 各组间ATA复发风险无差异。
- 各组间131I给药活度及首次131I治疗后131I亲和转移性疾病患病率无差异。
- 随访结束时(中位5.7年),各组进一步治疗次数无差异。
- 随访结束时(中位5.7年),各组临床反应无差异。
临床怎么用
- 作者认为DTC术后评估及治疗和随访策略应基于一般人群适用的风险分层,无需考虑BMI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is a risk factor for several cancers, including differentiated thyroid cancer (DTC). Moreover, it has also been investigated as a potential risk factor for aggressiveness of DTC, but the data gathered so far are conflicting. The aim of our study was to evaluate the relationship between body mass index (BMI), aggressiveness of DTC at diagnosis, and clinical outcome. METHODS: We evaluated 1058 consecutive DTC patients treated with total thyroidectomy and enrolled at the time of first radioactive iodine (131I) treatment. Patients were divided into 4 groups based on their BMI: underweight (< 18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), and obese (≥ 30 kg/m2). Histological aggressiveness of DTC at the time of diagnosis and clinical outcome according to 2015 American Thyroid Association (ATA) guidelines were evaluated. RESULTS: No differences in histological features, ATA risk of recurrence, activity of 131I administered and prevalence of 131I avid metastatic disease after first131I treatment, have been demonstrated among the groups. Furthermore, at the end of follow up (median = 5.7 years), no differences were evident in the number of further treatments performed as well as in the clinical response. CONCLUSIONS: In our study group of Caucasian subjects, we could not demonstrate any association between BMI and aggressiveness of DTC, neither at the time of diagnosis nor during follow-up. These data indicate that postsurgical assessment and therapeutic attitude for treatment and follow-up of DTC should be based on the class of risk applied to the general population, with no concern for BMI.
引用
- Matrone A, Ceccarini G, Beghini M, et al. Potential Impact of BMI on the Aggressiveness of Presentation and Clinical Outcome of Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2020. PMID: 31875910. doi:10.1210/clinem/dgz312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。